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INTRODUCTION 
 
Alzheimer’s disease (AD) comprises about 60%–70% 
of all dementia cases [1]. Around 14–16 million 
Americans will be diagnosed with AD by 2050 unless 
new treatments are identified [2]. The incidence and 
burden of AD increase dramatically with age [3, 4]. 
Though AD has been studied since 1906, the exact 
causes and pathogenic mechanisms remain to be 
elucidated.  
Mounting evidence suggests that cerebral 
hypometabolism is strongly related with cognitive 
impairment in AD [5-7]. Not only is hypometabolism 
associated with impaired memory, but it is also thought 
as a predictor for the decline of a multitude of other 
cognitive functions. There is an inverse relationship 
between amyloid-β (Aβ) deposition and glucose 
metabolism [8]. Hypometabolism may be triggered by 
amyloid toxicity. Alternatively, hypometabolism can 
mediate and/ or exacerbate effects of amyloid toxicity. 
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ABSTRACT 
 
Alzheimer’s disease (AD) is manifested by regional cerebral hypometabolism. Sirtuin 3 (Sirt3) is localized in 
mitochondria and regulates cellular metabolism, but the role of Sirt3 in AD-related hypometabolism remains 
elusive. We used expression profiling and weighted gene co-expression network analysis (WGCNA) to analyze 
cortical neurons from a transgenic mouse model of AD (APPSwInd). Based on WGCNA results, we measured 
NAD+ level, NAD+/ NADH ratio, Sirt3 protein level and its deacetylation activity, and ATP production across both 
in vivo and in vitro models. To investigate the effect of Sirt3 on amyloid-β (Aβ)-induced mitochondria damage, 
we knocked down and over-expressed Sirt3 in hippocampal cells. WGCNA revealed Sirt3 as a key player in Aβ-
related hypometabolism. In APP mice, the NAD+ level, NAD+/ NADH ratio, Sirt3 protein level and activity, and 
ATP production were all reduced compared to the control. As a result, learning and memory performance were 
impaired in 9-month-old APP mice compared to wild type controls. Using hippocampal HT22 cells model, Sirt3 
overexpression increased Sirt3 deacetylation activity, rescued mitochondria function, and salvaged ATP 
production, which were damaged by Aβ. Sirt3 plays an important role in regulating Aβ-induced cerebral 
hypometabolism. This study suggests a potential direction for AD therapy.  
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At preclinical stages, hypometabolism serves as an 
accurate predictor of cognitive decline and characterizes 
AD [9-11]. As a result, it is vital to investigate the 
mechanism of cerebral hypometabolism in AD. 
Multiple proteins within the mitochondria 
synergistically modulate Adenosine Triphosphate 
(ATP) production. Specifically, a key mitochondrial 
Nicotinamide adenine dinucleotide (NAD)+-dependent 
protein, Sirtuin 3 (Sirt3), plays an important role in 
energy metabolism [12, 13]. In our previous studies, 
Sirt3 was reduced in postmortem AD brains and its 
reduction was associated with declined cognitive 
performance and increased severity of AD pathology. 
Sirt3 was downregulated by Aβ-42 in primary cultured 
neurons [14, 15]. These studies suggest Sirt3 reduction 
plays an important role in pathogenesis of AD. 
However, little is known about the relationship between 
Sirt3-related energy regulation and hypometabolism in 
AD. 
 
In this study, expression profiling and weighted gene 
co-expression network analysis (WGCNA) provided the 
evidence that Sirt3-related energy pathway plays an 
important role in neuronal hypometabolism. The role of 
Sirt3 in hypometabolism was subsequently investigated 
using in vitro and in vivo models. Our findings show 
that Sirt3 rescues Aβ-induced ATP reduction and 
mitochondrial damage.  
RESULTS 
 
Amyloid precursor protein (APP) regulated Sirt3 
and its energy pathway 
 
WGCNA revealed that a list of molecules in energy 
metabolism changed significant in APP mice versus that 
in control mice including those that were closely related 
to the Sirt3 signal pathway (Table 1). In 9 month-old 
APP mouse brains, Sirt3 protein levels (1.81± 0.22) 
were significantly lower than that of the control (2.53± 
0.17, p<0.05, Fig. 1A, B). The NAD+ level and NAD+/ 
NADH ratio were directly related with Sirt3 activity. 
NAD+ level (Fig 1C) and the NAD+/NADH ratio (Fig. 
1D) showed statistically significant (p<0.05) decreases 
in APP mouse brains compared to controls. The 
deacetylation activity of Sirt3 in APP mice (3021± 
116.3 unit/ per µg protein) was consistently reduced 
compared to that of the control mice (4273.7± 262.1 
unit/ per µg protein, p< 0.01, Fig. 1E). In summary, 
Sirt3 protein expression, NAD+, NAD+/ NADH ratio, 
and Sirt3 activity were all down-regulated in APP mice.  
 
APP induced learning and memory deficits in mice 
 
We next tested whether or not cerebral hypometabolism 
of APP mice is translated into poor performance in 
Table 1. The effect of APP on gene expression of energy metabolism. 
Gene 
Name log2 fold p value Description 
 
PRKAA1 1.46493 0.0138586 protein kinase, AMP-activated, alpha 1 catalytic subunit  
SIRT3 production 
PPARG -2.7667 0.0003537 peroxisome proliferator-activated receptor gamma  
SIRT3 production 
USP3 1.36399 0.0352496 ubiquitin specific peptidase 3  
SIRT3 degradation 
PSMD3 -1.9837 0.0037322 
26S proteasome (prosome, macropain) non-ATPase 
regulatory subunit 3  
SIRT3 degradation 
ATPAF2 2.28485 0.0207859 
ATP synthase mitochondrial F1 complex assembly factor 
2  
Energy metabolism 
HMGCR -0.9487 0.0230069 3-hydroxy-3-methylglutaryl-CoA reductase 
Energy metabolism  
ACSS2 1.47603 0.0004182 acyl-CoA synthetase short-chain family member 2  
Energy metabolism 
INSR 0.89617 0.0102131 insulin receptor 
Energy metabolism 
IRS1 1.54338 0.0389107 insulin receptor substrate 1  
Energy metabolism 
MTFR1L 1.7624 0.0326343 mitochondrial fission regulator 1-like  
 
TOMM20 1.29106 0.049985 translocase of outer mitochondrial membrane 20  
 
Note: PRKAA1, PPARG, USP3 and PSMD3 are involved in SIRT3 synthesis and metabolism. 
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learning and memory. In Morris water maze (MWM) 
test, APP mice and age-matched WT mice had a similar 
baseline of escape latency on Day 1. During the four-
day learning test, the escape latency of APP mice was 
increased on Day 2 and continued to increase as 
compared to WT mice (Fig. 2A). These data indicated 
that APP mice showed less learning ability. In the probe 
trial on Day 5, APP mice spent less time in the target 
quadrant compared to WT mice (Fig. 2B). APP mice 
showed memory deficit in comparison to WT mice. In 
the novel object recognition (NOR) test, APP mice 
spent less time with novel objects compared to WT 
mice (Fig. 2C). This result indicated that APP mice 
could not remember well enough to differentiate the old 
object from the new one.  
 
Sirt3 activity is downregulated by Aβ-42 in vitro  
 
To test the effects of Aβ on Sirt3, we treated primary 
cortical neurons with oligomer Aβ-42 at varying 
concentrations. We chose oligomer Aβ-42 because it 
can freely enter neurons via a pore-forming mechanism, 
leading to subsequent calcium entry and mitochondrial 
damages [16-20]. Sirt3 protein levels were reduced in 
an Aβ-42 dose-dependent manner [14]. NAD+/ NADH 
ratio, as an important indicator of Sirt3 function, was 
decreased as the Aβ-42 concentration was increased 
(Fig. 3A). In isolated mitochondria, Sirt3 deacetylation 
activity was suppressed by Aβ-42 (Fig. 3B), so was the 
ATP production (Fig. 3C). The correlation analysis 
indicated that Sirt3 deacetylation activity was related 
with its protein levels in this study (Fig. 3D). These data 
provide evidence that Aβ-42 downregulated Sirt3 
expression and impairs its function in primary neurons.  
 
Sirt3 rescues mitochondrial function impaired by 
Aβ-42  
 
We further investigated whether Sirt3 overexpression 
could protect Aβ-42-induced mitochondria damages. 
Hippocampal HT22 cells were transfected by lentivirus 
containing Sirt3 cDNA (Sirt3 overexpression) or 
 
 
Figure 1. The protein expression and activity of Sirt3 are reduced in APP mice.  Mouse fresh brain tissues were collected and 
homogenized. (A, B) Sirt3 protein expression by Western blot was lower in APP than WT mice. (C) NAD+ level and (D) NAD+/ NADH ratio 
were reduced in APP mice compared to WT mice. (E) Mitochondria were isolated from mouse brain to test Sirt3 deacetylation activity 
(ratio of fluorescent intensity to total protein). Sirt3 activity in APP mice was lower in APP mice than that in WT mice. Note: n=3 per 
group, * p<0.05. 
 
 
 
Figure 2. Learning and memory is impaired in APP mice. APP mice (n=11) and age-matched WT mice (n=12) were tested in 
MWM and NOR tests. (A) The escape latency was measured during the 4-day period. APP mice had a longer latency than WT mice. (B) 
The time spent in the target quadrant was measured on Day 5. APP mice spent much less time there than WT mice.  (C) NOR 
discrimination index between APP and WT groups. *p< 0.05.  
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shRNA (Sirt3 knockdown) (Fig. 4A-C). Transfection 
was confirmed using Western blot [Sirt3 overexpression 
(6.1± 0.5%, p< 0.01), expression knock down (2.2± 0.2 
%, p< 0.05) vs. vector control (3.5±0.2%)] (Fig. 4D and 
E). Sirt3 deacetylation activity in isolated mitochondria 
was reduced in Sirt3 knockdown cells and increased in 
Sirt3 overexpressing cells. This activity was also 
reduced in Aβ-42 treated groups compared to their 
untreated counterpart. Compared to the vector control 
group (6148± 524), Sirt3 deacetylation activities were 
3599± 428 (p< 0.01) in the vector treated with Aβ-42, 
3682± 353 (p< 0.01) in shRNA cells, and 2506± 239 
(p< 0.01) in shRNA treated with Aβ-42. Sirt3 
deacetylation activity was increased in Sirt3 
overexpression cells (8985± 475, p< 0.01) (Fig. 4F). 
This increased Sirt3 deacetylation activity was 
translated into enhancing mitochondrial function 
including the increased ATP production. Compared to 
the vector control group (100.2± 5.7), Aβ-42 treatment 
reduced intracellular ATP levels (63.5± 4.6, p< 0.01). 
Sirt3 knockdown showed further reduction [shRNA 
(71.3± 5.2, p< 0.05) and shRNA plus Aβ-42 (39.6±3.8, 
p< 0.01)]; whereas Sirt3 overexpression increased ATP 
levels by almost 40% (137.2± 9.2, p< 0.01, Fig. 4G).  
 
DISCUSSION 
 
Cerebral hypometabolism is one of the early signs of 
AD and is thought to be a predictor of disease 
progression [5-7]. Although there is no evidence of 
chronic ischemia, regional cerebral glucose 
hypometabolism is consistent in AD patients and is 
correlated with the severity of dementia [21, 22]. Since 
Aβ also occurs early in the course of the disease, there 
is a close relationship between Aβ deposition and 
reduced cerebral glucose metabolism [8]. Up to 40% of 
the effects of Aβ on episodic memory are attributable to 
hypometabolism as measured by FDG-PET [5]. Aβ 
treatment for 24 hours decreased ATP levels in human 
stem cell-derived neurons and astrocyte cultures. 
Interestingly, the NAD+/NADH ratio was increased first 
and then reduced [23]. The APP mouse model 
demonstrates amyloid deposition at 6 months and is 
ideal for investigating Aβ-induced hypometabolism.  
 
Our previous study has demonstrated that Sirt3 is 
involved in AD pathology that is triggered by Aβ. This 
study further explored the relationship between Sirt3-
related energy pathway and Aβ-induced 
hypometabolism in AD. Our data showed Sirt3 protein 
and its functions were significantly downregulated in 
both APP mice and Aβ-42-treated primary neurons. 
With genetic enhancement of its expression, Sirt3 
overexpression partially rescued cellular energy 
metabolism damaged by Aβ-42. 
 
WGCNA and pathway analysis of APP mice revealed 
several key molecules related to Sirt3. Peroxisome 
proliferator-activated receptor gamma coactivator-1α 
(PGC-1α) stimulates Sirt3 expression at both mRNA 
and protein levels [24], in an estrogen-related receptor α 
(ERRα)-dependent manner [25]. Co-transfection of 
PGC-1α and ERRα has a synergic effect on Sirt3 
activity [24]. The mRNA of peroxisome proliferator-
activated receptor gamma in APP mouse brain was 
reduced compared to WT mice brains (Table 1), 
suggesting the production of Sirt3 may be down-
regulated in APP mice. The ubiquitin proteasome 
pathway (UPP) is responsible for degradation of 
intracellular proteins. The 26S proteasome is distributed 
throughout eukaryotic cells at a high concentration and 
cleaves peptides in an ATP/ ubiquitin-dependent 
process. Evidence indicates that Sirt3 is ubiquitinated 
and the E3 ubiquitin ligase is involved in Sirt3 
degradation [26, 27]. Loss of ubiquitin-specific 
 
 
Figure 3. Sirt3 activity is downregulated by Aβ-42 in vitro. Primary cortical neurons were treated with Aβ-42 (0, 10,100,1000 ng/ 
ml) for 24 hours. (A) NAD+/ NADH ratio; (B) Mitochondrial Sirt3 deacetylation activity (the ratio of fluorescent intensity to total protein); 
(C) ATP levels were decreased when Aβ-42 concentration was increased. (D) The correlation between Sirt3 protein levels and its 
deacetylation activity. n=6 per group, * p< 0.05, **p< 0.01.   
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peptidase 3 (USP3) increased the levels of histone 
ubiquitination in adult tissues, and shortened animal life 
span [28]. In APP mouse brains, USP3 expression was 
significantly higher than WT mice, suggesting that the 
degradation of Sirt3 may be up-regulated in APP mice. 
Sirt3 deacetylates several mitochondrial proteins, 
including long-chain acyl-CoA dehydrogenase, Acetyl-
coenzyme A synthetase 2 (AceCS2) and 3-hydroxy-3-
methylglutaryl CoA synthase 2. Deacetylation of 
AceCS2 by Sirt3 activates the acetyl-CoA synthetase 
activity of AceCS2 [29]. Thus, Sirt3 deacetylation 
activity can affect the ATP energy pathway. 
Mitochondrial ATP synthase is a large protein complex 
located in the mitochondrial inner membrane, where it 
catalyzes ATP synthesis. ATP synthase mitochondrial 
F1 complex assembly factor 2 (ATPAF2) facilitates the 
biogenesis of ATP synthase [30]. In APP mouse brain, 
ATPAF2 expression was down-regulated in comparison 
to WT mice. This change suggests that the Sirt3-related 
energy pathway may play an important role in ATP 
production.  
 
Pursuing the lead following WGCNA and pathway 
analysis, we systemically studied the effects of Aβ on 
changes in Sirt3 expression and activity both in vivo 
and in vitro. We found that NAD+, NAD+/NADH ratio, 
Sirt3 protein levels and activities were noticeably 
reduced in APP mouse brain compared to WT. By 
genetic modification, Sirt3 knockdown showed further 
decline in ATP production, whereas Sirt3 
overexpression helped to rescue Aβ-induced 
hypometabolism.  
 
The association between Aβ toxicity, mitochondrial 
dysfunction, oxidative stress and neuronal death has 
been well studied. Aβ increases production of 
mitochondrial ROS [31] and mitochondrial Ca++ 
mobilization may contribute to this process [32]. 
Because mitochondrial DNA is inherited maternally, 
brain hypometabolism is more pronounced in AD 
patients who have a maternal family history of AD than 
those with a paternal family history or those with a 
negative family history [33]. 
 
Sirt3 is localized in mitochondria and plays a critical 
role in ATP production. The Sirt3 signal pathway has 
been studied in neurodegenerative diseases. β-
hydroxybutyrate, a potent Sirt3 agonist, blocked the 
 
 
Figure 4. Sirt3 rescues mitochondrial function impaired by Aβ-42. (A) HT22 cells were successfully transfected (green) with 
vector, Sirt3 cDNA or shRNA. The percentage of transfection was analyzed on Accuri C6 Flow Cytometer. (B) Before transfection, the 
percentage was 0 (negative control); (C) After transfection, there were 94.7% cells transfected. Sirt3 protein levels in transfected cells 
were further confirmed by using Western blot. (D) A representative Western blot of Sirt3. β-actin was used as an internal control. (E) In 
transfected cells, Sirt3 protein levels were measured with normalization with β-actin. (F) Sirt3 deacetylation activity (the ratio of 
fluorescent intensity to total protein) and (G) ATP levels were tested in isolated mitochondria. N= 6 per group,  *p< 0.05, **p< 0.01 vs. 
vector; #p< 0.05, ##p< 0.01 vs. respective treated group. 
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entry of Aβ into the neurons and restored mitochondria 
functions, which attenuated cognitive decline in this 
APP mouse model of AD [16]. In animal models of 
hypertension, cardiac disease and ischemic stroke, Sirt3 
has shown to suppress oxidative stress by regulating 
NOX2, NOX4, SOD2, Nrf2 and FoxO3a [34-37]. 
 
In conclusion, these data suggest that Sirt3 plays an 
important role in pathophysiology at an early stage of 
development of AD. The rescuing effects of Sirt3 on 
mitochondria and ATP production may provide a 
potential disease-modifying target for AD therapy. 
 
MATERIALS AND METHODS 
 
Animals  
 
All experiments involving animals were performed 
following protocols in accordance to the Revised Guide 
for the Care and Use of Laboratory Animals that was 
approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Barrow Neurological 
Institute.  
 
J20 transgenic mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). These transgenic mice 
express a mutant form of the human APP. They have 
both the Swedish (K670N/M671L) and the Indiana 
(V717F) mutations (APPSwInd). Diffuse Aβ deposition 
starts to appear in the dentate gyrus and neocortex at 
age 5-7 months. It is progressive with all transgenic 
mice exhibiting plaques by age 8-10 months [38]. We 
used 9 month-old APP mice and age-matched wild type 
(WT) mice with the same B6 background (12-14 
animals per group).  
 
Behavioral studies 
 
The MWM was used to test spatial learning and 
memory function as described previously [39]. Mice 
were given 6 trials per day for 4 days, with an inter-trial 
interval of 20 minutes. A single probe trial was carried 
out 24 hours after the hidden platform task had been 
completed. Medial temporal lobe and frontal lobe 
function was assessed using the NOR test [40]. Twenty-
four hours prior to the NOR test, mice were habituated 
to the empty open field for 10 minutes. During training, 
mice were placed in the center of the open field 
containing two identical objects, and the time spent 
exploring each object during a 5-minute period was 
quantified. Four hours later, the mice were tested by 
replacing one of the identical objects with a novel 
object of different shape and color. Novel object 
recognition was quantified using the discrimination 
index (DI) calculated as: DI= (Exploration Time for 
Novel object - Exploration Time for Familiar object)/ 
Total Exploration time. 
 
Preparation of mouse brain tissue  
 
Mice were euthanized by injection of a 
ketamine/xylamine cocktail at 9 months. Fresh brain 
tissues (temporal cortex) were quickly collected on ice. 
Parts of fresh brain tissues were used immediately for 
NAD+ and NADH measurement, Sirt3 deacetylation 
activity test after mitochondrial isolation. The fresh 
temporal cortex was stored at −80°C for Sirt3 protein 
level test in western blotting. For weighted gene co-
expression network analysis, mice brains were 
harvested and frozen, sectioned (8 μm), and fixed on 
glass slides. 
 
Weighted Gene Co-expression Network analysis  
 
Mouse brain samples (n=6 in each group) were used for 
transcriptomic analyses as described previously [41]. 
Brain sections were stained with a combination of 
thioflavin-S (Sigma-Aldrich, Dallas, TX) and 1% 
neutral red (Fisher Scientific, Chicago, IL). Pyramidal 
neurons were detected and laser-captured. Total RNA 
was isolated using the Arcturus PicoPure RNA Isolation 
Kit with DNase I treatment (Qiagen, Valencia, CA). 
Isolated total RNA from each sample of approximately 
500 neurons was double-round amplified, cleaned, and 
biotin-labeled with Affymetrix’s GeneChip per the 
manufacturer’s protocol. Amplified and labeled 
complementary RNA was quantified on a 
spectrophotometer and run on a 1% Tris-acetate-EDTA 
gel to check for an evenly distributed range of transcript 
sizes.  
 
Data analysis: Following completion of sequencing, we 
initiated an automated in-house pipeline for NGS 
analysis through our laboratory database. BCL 
conversion was performed using Illumina’s BCL 
Converter and FASTQ alignments was aligned using 
STAR [42]. Alignment produced single BAM files 
containing both aligned and unaligned data. DEseq2 
was used to identify differentially expressed transcripts 
and p-values was corrected using the Benjamini and 
Hochberg False Discovery Rate [43]. Gene annotation 
was performed based on Gencode version 3 
(ENSEMBL) and build 37.1. WGCNA was performed 
on differentially expressed genes (corrected p < 0.05) 
[44, 45]. Gene sets were loaded into the WGCNA R 
package, and annotation of generated modules was 
performed using DAVID [46]. We chose genes that are 
known to be Sirt3 related in the energy metabolism 
pathway.  
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Primary neuron cultures 
 
Primary cortical neuron cultures were prepared from 
new-born mouse pups as described previously [14, 34]. 
Briefly, cortical neurons grew on poly-D-lysine coated 
dishes in neuronal culture media. On day 14th, cultured 
neurons were treated with Aβ-42 (0, 10,100,1000ng/ml) 
for 24 hours, and then further measures were carried out 
as described in the text. 
 
Preparation of oligomeric Aβ-42  
 
Human synthetic Aβ-42 (rPeptide) was treated in 20 
µM ammonium acetate in distilled water and incubate 
for 30 minutes at room temperature, then lyophilized 
and stored at -800C. The pretreated Aβ-42 was 
dissolved in artificial cerebrospinal fluid (aCSF) or 
culture media at room temperature immediately prior to 
use. The presence and stability of oligomers was tested 
by electron microscopy and western blot techniques [14, 
16). 
 
Sirt3 vector construction and transfection  
 
Sirt3 was either over-expressed or knocked down as 
described previously [14, 34] with modifications in 
hippocampal HT22 cells. HT22 cells grew in DMEM 
medium (ThermoFisher Scientific, #12491015) plus 
10% fetal bovine serum and 1% penicillin-
streptomycin-glutamine (ThermoFisher Scientific, 
#10378-016) in humidified incubator (37C, 5%CO2). 
After cells grew 70% confluent in 6 wells plate, fresh 
media with lentiviral particles (multiplicity of infection 
=20) was added. On next day, media with lentiviral 
particles was removed and replaced fresh media. Then, 
media with puromycin (3ug/ml) was added and replaced 
media with puromycin every 3-4 days. HT22 cells with 
successfully transfected with vector, Sirt3 or shRNA 
containing green fluorescent protein (GFP) were 
checked under fluorescent microscope. Transfected 
HT22 cells grew in media with puromycin (3ug/ml) and 
were treated with Aβ-42 for 24 hours; and then further 
measures were carried out as described in the text.  
 
Mitochondrial isolation  
 
Mitochondria were isolated from cells or fresh brain 
tissues as we described previously [15, 34]. Cells/ 
tissues were collected and was homogenized using 
dounce homogenizer (for cells) or glass homogenizer 
(for tissue) in mitochondrial isolation buffer (320 mM 
sucrose, 1 mM EDTA, and 10 mM Tris-HCl, pH=7.4) 
on ice. The homogenate was centrifuged 1000×g at 4°C 
for 10 min and the supernatant was collected. The 
supernatant was spin for 20 min at 13000×g at 4°C. The 
resulting pellet was resuspended in mitochondrial 
respiration buffer (110 mM sucrose, 0.5 mM EGTA, 
3mM MgCl2, 40 mM KCl, 10 mM KH2PO4, 20 mM 
HEPES, 1g/l BSA) to make mitochondrial sample 
solution. 
 
NAD+ and NADH measurement  
 
NAD+, NADH measurement in tissues or cells was 
carried out as described previously [14, 34].   Total 
NAD+ and NADH were tested using an NAD+/ NADH 
assay kit (ab65348, Abcam, Cambridge, MA) according 
to the manufacturer’s protocol. NAD+/ NADH ratio was 
calculated based on the value of total NAD+ and NADH 
(NAD+= total NAD+– NADH). 
 
ATP level measurement in cultured cells 
 
ATP levels were measured as described previously [14]. 
Cultured cells were seeded in a 96-well plate (2.5 x104 
cells per well, n= 6 wells per group) and treated with 
oligo Aβ-42 for 24 hours before further measurement. 
ATP levels were measured using a Luminescent ATP 
detection assay kit (#ab113849, Abcam, Cambridge, 
MA) according to the manufacturer’s protocol. The 
ATP value of vector cells without Aβ-42 treatment was 
normalized to 100%. 
 
Mitochondrial Sirt3 deacetylation activity 
 
After mitochondria were isolated from cells or brain 
tissues, Sirt3 deacetylation activity was measured using 
Sirt3 activity assay kit (#ab156067, Abcam, Cambridge, 
MA) following the manufacturer’s protocol. The 
fluorescent intensity was collected on Tecan infinity 
M200 pro according to the manufacturer’s protocol and 
was normalized with the amount of total test protein. 
Final data were normalized with total protein 
concentration from cells or tissues.  
 
Sirt3 deacetylation activity was represented as the ratio 
of fluorescent intensity to the amount of total test 
protein and the ratio was used for statistical analysis.  
 
Western blot  
 
Fifty µg protein was used for Western blotting. Primary 
antibodies were the following: anti-Sirt3 (#5490S, Cell 
Signaling, Danvers, MA), anti-β-actin (Santa Cruz, 
Dallas, TX), IRDye 800CW and IRDye 680CW 
antibodies (LI-COR, Lincoln, NE). Immunoreactivity 
signals were quantified using Odyssey CLx (LI-COR, 
Lincoln, NE). Protein levels were presented as a 
percentage relative to β-actin, an internal control.  
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Statistical analysis 
 
Data are expressed as mean± SEM. An unpaired 
Student’s T-test was used for comparison between the 
two groups to determine the significance of the 
difference by using the GraphPad Prism 4.0 software. A 
value of p< 0.05 was considered significant.  
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